These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35707463)

  • 1. Therapeutic Potential of Targeting Periostin in the Treatment of Graves' Orbitopathy.
    Jang SY; Kim J; Park JT; Liu CY; Korn BS; Kikkawa DO; Lee EJ; Yoon JS
    Front Endocrinol (Lausanne); 2022; 13():900791. PubMed ID: 35707463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yes-Associated Protein Mediates the Transition from Inflammation to Fibrosis in Graves' Orbitopathy.
    Ko J; Kim YJ; Choi SH; Lee CS; Yoon JS
    Thyroid; 2023 Dec; 33(12):1465-1475. PubMed ID: 37800725
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic role of histone deacetylase inhibition in an
    Byeon HJ; Choi SH; Kikkawa DO; Ko J; Yoon JS
    Mol Med Rep; 2024 Dec; 30(6):. PubMed ID: 39329199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Adipsin, Complement Factor D, in the Pathogenesis of Graves' Orbitopathy.
    Byeon HJ; Chae MK; Ko J; Lee EJ; Kikkawa DO; Jang SY; Yoon JS
    Invest Ophthalmol Vis Sci; 2023 Aug; 64(11):13. PubMed ID: 37555734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentraxin 3 mediates inflammation and adipogenesis in Graves' orbitopathy pathogenesis.
    Kim MS; Park HY; Choi SH; Chang EJ; Ko J; Yoon JS
    J Mol Endocrinol; 2024 Nov; 73(4):. PubMed ID: 39283923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Therapeutic Role of Bone Morphogenic Protein 7 (BMP7) in the Pathogenesis of Graves' Orbitopathy.
    Kim BY; Choi SH; Kim JY; Ko J; Yook JI; Kim HS; Lee EJ; Kikkawa DO; Yoon JS
    Invest Ophthalmol Vis Sci; 2022 Jun; 63(6):7. PubMed ID: 35671049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PERK mediates oxidative stress and adipogenesis in Graves' orbitopathy pathogenesis.
    Ko J; Kim JY; Kyoung Chae M; Jig Lee E; Sook Yoon J
    J Mol Endocrinol; 2021 May; 66(4):313-323. PubMed ID: 33870911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves' Orbitopathy in Orbital Fibroblasts.
    Lee GE; Kim J; Lee JS; Ko J; Lee EJ; Yoon JS
    Front Endocrinol (Lausanne); 2020; 11():607144. PubMed ID: 33488522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycogen Synthase Kinase-3β Mediates Proinflammatory Cytokine Secretion and Adipogenesis in Orbital Fibroblasts from Patients with Graves' Orbitopathy.
    Lee JS; Chae MK; Kikkawa DO; Lee EJ; Yoon JS
    Invest Ophthalmol Vis Sci; 2020 Jul; 61(8):51. PubMed ID: 32735324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disulfiram Exerts Antiadipogenic, Anti-Inflammatory, and Antifibrotic Therapeutic Effects in an
    Wang X; Yang S; Ye H; Chen J; Shi L; Feng L; Wang X; Zhang T; Chen R; Xiao W; Yang H
    Thyroid; 2022 Mar; 32(3):294-305. PubMed ID: 34605662
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy.
    Ko J; Kim JY; Lee EJ; Yoon JS
    Invest Ophthalmol Vis Sci; 2018 Sep; 59(11):4477-4485. PubMed ID: 30193323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signal transducer and activator of transcription 3 as a potential therapeutic target for Graves' orbitopathy.
    Ko J; Kim JY; Kim BR; Lee EJ; Kikkawa DO; Yoon JS
    Mol Cell Endocrinol; 2021 Aug; 534():111363. PubMed ID: 34116129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tanshinone IIA in an in vitro model of Graves' orbitopathy.
    Rhiu S; Chae MK; Lee EJ; Lee JB; Yoon JS
    Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):5900-10. PubMed ID: 25159204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokine Expression during Adipogenesis and Inflammation in Orbital Fibroblasts from Patients with Graves' Orbitopathy.
    Lee CE; Choi SH; Yoon JS
    Korean J Ophthalmol; 2020 Jun; 34(3):192-202. PubMed ID: 32495527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of binding immunoglobulin protein (BiP) in Graves' orbitopathy pathogenesis.
    Ko J; Kim JY; Lee EJ; Yoon JS
    J Mol Endocrinol; 2021 Jan; 66(1):71-81. PubMed ID: 33112798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.
    Park HY; Chae MK; Ko J; Kikkawa DO; Jang SY; Yoon JS
    PLoS One; 2022; 17(12):e0279060. PubMed ID: 36521376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-Methylumbelliferone suppresses hyaluronan and adipogenesis in primary cultured orbital fibroblasts from Graves' orbitopathy.
    Yoon Y; Chae MK; Lee EJ; Yoon JS
    Graefes Arch Clin Exp Ophthalmol; 2020 May; 258(5):1095-1102. PubMed ID: 31900640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biguanides Metformin and Phenformin Generate Therapeutic Effects via AMP-Activated Protein Kinase/Extracellular-Regulated Kinase Pathways in an In Vitro Model of Graves' Orbitopathy.
    Han YE; Hwang S; Kim JH; Byun JW; Yoon JS; Lee EJ
    Thyroid; 2018 Apr; 28(4):528-536. PubMed ID: 29589999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein tyrosine phosphatase 1B as a therapeutic target for Graves' orbitopathy in an in vitro model.
    Byeon HJ; Kim JY; Ko J; Lee EJ; Don K; Yoon JS
    PLoS One; 2020; 15(8):e0237015. PubMed ID: 32760098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human placenta-derived mesenchymal stem cells ameliorate orbital adipogenesis in female mice models of Graves' ophthalmopathy.
    Park M; Banga JP; Kim GJ; Kim M; Lew H
    Stem Cell Res Ther; 2019 Aug; 10(1):246. PubMed ID: 31399042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.